788 related articles for article (PubMed ID: 14601692)
41. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID).
Wang J; Cunningham-Rundles C
J Autoimmun; 2005 Aug; 25(1):57-62. PubMed ID: 15994061
[TBL] [Abstract][Full Text] [Related]
42. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
D'Arena G; Laurenti L; Capalbo S; D'Arco AM; De Filippi R; Marcacci G; Di Renzo N; Storti S; Califano C; Vigliotti ML; Tarnani M; Ferrara F; Pinto A
Am J Hematol; 2006 Aug; 81(8):598-602. PubMed ID: 16823816
[TBL] [Abstract][Full Text] [Related]
43. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab.
Ramanathan S; Koutts J; Hertzberg MS
Am J Hematol; 2005 Feb; 78(2):123-6. PubMed ID: 15682420
[TBL] [Abstract][Full Text] [Related]
44. Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency.
Carbone J; Escudero A; Mayayo M; Ballesteros M; Perez-Corral A; Sanchez-Ramon S; Sarmiento E; Micheloud D; Fernandez-Cruz E
Ann N Y Acad Sci; 2005 Jun; 1051():666-71. PubMed ID: 16127007
[TBL] [Abstract][Full Text] [Related]
45. [Evans' syndrome: a retrospective study from the ship (French Society of Pediatric Hematology and Immunology) (36 cases)].
Blouin P; Auvrignon A; Pagnier A; Thuret I; Antoni G; Bader-Meunier B; Le Deist F; Chastagner P; Aladjidi N; Pellier I; Bertrand Y; Behar C; Landmann-Parker J; Leverger G; Perel Y
Arch Pediatr; 2005 Nov; 12(11):1600-7. PubMed ID: 16185853
[TBL] [Abstract][Full Text] [Related]
46. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?
Cooper N; Evangelista ML; Amadori S; Stasi R
Curr Opin Hematol; 2007 Nov; 14(6):642-6. PubMed ID: 17898569
[TBL] [Abstract][Full Text] [Related]
47. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura.
Riksen NP; Keuning JJ; Vreugdenhil G
Neth J Med; 2003 Jul; 61(7):262-5. PubMed ID: 14567524
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies.
Reynaud Q; Durieu I; Dutertre M; Ledochowski S; Durupt S; Michallet AS; Vital-Durand D; Lega JC
Autoimmun Rev; 2015 Apr; 14(4):304-13. PubMed ID: 25497766
[TBL] [Abstract][Full Text] [Related]
49. [Successful treatment with rituximab in a patient with refractory mixed-type autoimmune hemolytic anemia].
Ono K; Sato T; Iyama S; Tatekoshi A; Hashimoto A; Kamihara Y; Horiguchi H; Kikuchi S; Takada K; Hayashi T; Miyanishi K; Sato Y; Takimoto R; Kobune M; Kato J
Rinsho Ketsueki; 2013 Nov; 54(11):2053-5. PubMed ID: 24305538
[TBL] [Abstract][Full Text] [Related]
50. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
Schweizer C; Reu FJ; Ho AD; Hensel M
Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
[TBL] [Abstract][Full Text] [Related]
51. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases.
Michel M; Chanet V; Dechartres A; Morin AS; Piette JC; Cirasino L; Emilia G; Zaja F; Ruggeri M; Andrès E; Bierling P; Godeau B; Rodeghiero F
Blood; 2009 Oct; 114(15):3167-72. PubMed ID: 19638626
[TBL] [Abstract][Full Text] [Related]
52. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.
Osterborg A; Karlsson C; Lundin J
Curr Hematol Malig Rep; 2009 Jan; 4(1):47-53. PubMed ID: 20425438
[TBL] [Abstract][Full Text] [Related]
53. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia.
Gupta N; Kavuru S; Patel D; Janson D; Driscoll N; Ahmed S; Rai KR
Leukemia; 2002 Oct; 16(10):2092-5. PubMed ID: 12357362
[TBL] [Abstract][Full Text] [Related]
54. New treatment options for immune-mediated hematological disorders.
Dierickx D; De Rycke A; Vanderschueren S; Delannoy A
Eur J Intern Med; 2008 Dec; 19(8):579-86. PubMed ID: 19046722
[TBL] [Abstract][Full Text] [Related]
55. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
Kumar S; Benseler SM; Kirby-Allen M; Silverman ED
Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
[TBL] [Abstract][Full Text] [Related]
56. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
[TBL] [Abstract][Full Text] [Related]
57. Sirolimus is effective for primary relapsed/refractory autoimmune cytopenia: a multicenter study.
Li H; Ji J; Du Y; Huang Y; Gu H; Chen M; Wu R; Han B
Exp Hematol; 2020 Sep; 89():87-95. PubMed ID: 32771553
[TBL] [Abstract][Full Text] [Related]
58. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
Zhou Z; Yang R
Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
[TBL] [Abstract][Full Text] [Related]
59. Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP).
Gómez-Almaguer D
Hematology; 2012 Apr; 17 Suppl 1():S25-7. PubMed ID: 22507772
[TBL] [Abstract][Full Text] [Related]
60. Rituximab for refractory childhood autoimmune hemolytic anemia.
Motto DG; Williams JA; Boxer LA
Isr Med Assoc J; 2002 Nov; 4(11):1006-8. PubMed ID: 12489491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]